Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Feinberg Receives $1.5 Million Grant for Cutting-Edge Brain Research
Uncategorized

Feinberg Receives $1.5 Million Grant for Cutting-Edge Brain Research

By medwebFeb 2, 2012
Share
Facebook Twitter Email

Northwestern Medicine® was named one of 25 sites nationwide to take part in a seven-year, $84 million plus initiative that could speed up medical research and find new drug therapies for some of the most devastating neurological diseases and disorders.

The National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), awarded Northwestern University Feinberg School of Medicine a $1.5 million grant to participate in the newly formed NeuroNEXT, a Network for Excellence in Neuroscience Clinical Trials. Feinberg is the only institution in Illinois to be named a NeuroNEXT site.

Tanya Simuni, MD, the Arthur C. Nielsen Jr. research professor and director of the Parkinson’s Disease and Movement Disorders Center, will lead the site at Feinberg.

The first NeuroNEXT study could start as early as March and will focus on validating the biomarkers of a neurological condition called spinal muscular atrophy.

“It’s a genetic neuromuscular disorder affecting kids and potentially young adults,” Simuni said. “Right now, there is no known cure for the disease.”

If a promising biomarker for spinal muscular atrophy is found, researchers could move forward on finding treatments for the disease.

“There are often significant delays and large start-up costs when a multi-site consortium is formed to conduct a federally-funded study,” Simuni said. “The NeuroNEXT initiative is a first-of-its-kind undertaking by the NINDS to eliminate those hurdles by bringing together selected institutions capable of conducting many different studies across neurological disciplines.”

All 25 NeuroNEXT sites will report to one central ethics review board and one data center. Simuni said this increases efficiency and productivity and allows the consortium to conduct many more of the important phase-two “exploratory” trials over the next several years.

The NeuroNEXT model also allows Feinberg researchers the rare opportunity to use the efficient infrastructure to submit their own ideas for neuroscience research. Outside academic institutions, advocacy groups, and foundations, small businesses and the pharmaceutical industry are also welcome to propose research ideas to NeuroNEXT.

“Anyone who has a promising idea to advance neuroscience research has a chance for their proposal to be evaluated by this efficient system,” Simuni said.

Share. Facebook Twitter Email

Related Posts

Lurie Cancer Center Receives Merit Extension from NCI

Oct 20, 2021

Drug Combination May Reduce Risk of Leukemia Relapse

Mar 26, 2020

Rewriting the Role of a Transcription Factor

Mar 19, 2020

Comments are closed.

Latest News

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Combination Treatment May Improve Quality of Life in Kidney Cancer

Jun 23, 2022

Calcium Channel Blockers May Improve Chemotherapy Response

Jun 21, 2022

Expanded Role for Calcium Channels in T-Cells

Jun 17, 2022
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20220607_Feinberg Campus_0070
20220607_Feinberg Campus_0066
20220607_Feinberg Campus_0054
Northwestern University 2022. Photo by Jim Prisching
20220607_Feinberg Campus_0077
20220607_Feinberg Campus_0063
20220607_Feinberg Campus_0111
20220607_Feinberg Campus_0083
20220607_Feinberg Campus_0018
20220607_Feinberg Campus_0023
20220607_Feinberg Campus_0072 (2)
20220607_Feinberg Campus_0120

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2022 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.